The decreased level of apoA-I in plasma is observed in the case of de novo myelodysplastic syndromes [83], NSCLC [84], nasopharyngeal carcinoma (NPC) [85], esophageal squamous cell carcinoma [86], and BC [75], but it is increased in SCLC, HCC, and bladder cancer [80]. This evidence concerns the gene APOA1 and breast cancer.